Hem

Press release from Companies

Publicerat: 2021-06-29 08:07:40

Cessatech A/S: Cessatech announces new Chairman of the Board - getting ready for the pivotal studies

The Board of Directors of Cessatech A/S ("Cessatech" or the "Company") has appointed Adam Steensberg as new Chairman of the Board. The appointment follows significant business progress following the successful IPO in December. Ulla Buhl will continue as a member of the Board of Directors.

On 29 June 2021 Cessatech A/S announces that the Board of Directors has appointed Adam Steenberg as the new Chairman of the Board as of July 1st, 2021. Adam Steensberg is Chief Medical Officer and Head of R&D at Zealand Pharma and has been on the Board of Cessatech since August 2020. His experience in bringing medicines through late-stage development to commercialization will be important as Cessatech moves into the next development phase with the planned initiation of the first pivotal trial for CT001 in the second half of 2021.

Comment from Jes Trygved, CEO of Cessatech
I am very pleased with the appointment of Adam, he has extensive development and leadership experience which are very strong assets to the further advancement of Cessatech. I would like to thank Ulla for her great chairmanship during the last years and in particular the IPO process and look forward continuously working with the Board on realizing our commitment to the patients.

Comment from Adam Steensberg, Chairman of the Board of Directors, Cessatech
Since joining the Board of Directors I have been truly impressed with the scientific rigor, quality and speed with which the company operates and look forward working with Jes and the team to progress our mission of bringing innovative new medicines to children.

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children.
CT001 is expected to enter late stage clinical development in 2021.

Läs mer hos Cision
Läs mer om Cessatech A/S

Prenumeration